Is more better? An immune-based approach to anti-HPV vaccine efficacy

Rafał Pawliczak

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2010
vol. 9

Send email

Copy url:

abstract:

Review paper

Is more better? An immune-based approach to anti-HPV vaccine efficacy

Rafał Pawliczak

Przegląd Menopauzalny 2010; 2: 109–112

Online publish date: 2010/05/12

View full text Get citation

Summary
Natural history studies conducted over the past 20 years have demonstrated that human papillomavirus (HPV) infection is a necessary prerequisite for the development of cervical cancer, the second most frequent cause of death in young women. Recently, two anti-HPV vaccines have been approved for immunoprophylaxis of cervical cancer: a quadrivalent vaccine containing L1 virus-like particles (VLPs) of HPV types 6, 11, 16 and 18, and a bivalent vaccine containing VLPs of types 16 and 18. In efficacy trials involving young women, both vaccines produced outstanding efficacy against primary and secondary endpoints associated with the vaccine type HPVs and were highly and consistently immunogenic. This review is focused on comparing safety and efficacy of both available vaccines.

keywords:

Is more better? An immune-based approach to anti-HPV vaccine efficacy

Rafał Pawliczak

cervical cancer, immunoprophylaxis, HPV